Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units ("RSUs") to one newly hired employee.
2024年7月1日，馬薩諸塞州查爾斯頓（GLOBE NEWSWIRE）—— Solid Biosciences Inc.（納斯達克：SLDB）（“公司”）是一家生命科學公司，致力於開發用於神經肌肉和心臟疾病的精準基因藥物，今天宣佈向一名新僱員授予11847個受限股票單位（“RSUs”）。
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee's continued service with the Company through each applicable vesting date.
股票將在授予日起到第四個週年紀念日的四個等額分期歸屬。權益獎勵的歸屬取決於員工在每個適用的歸屬日期之前繼續服務於公司。
This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
該批股票是根據公司的2024年引誘性股票激勵計劃授予，並根據納斯達克上市規則5635(c)(4)與僱員的就業接受有關而作爲誘因。
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
關於固體生物科學（Solid Biosciences）
Solid Biosciences 是一家生命科學公司，專注於推進一系列基因治療候選藥物，包括用於治療杜興氏肌萎縮症 (Duchenne) 的 SGT-003、用於治療兒茶酚胺多形性室性心動過速 (CPVT) 的 SGT-501、用於治療BAG3介導的擴張型心肌病的AVB-401，以及其他用於治療致命心臟病的資產。Solid正在推進其在罕見的神經肌肉和心臟疾病領域的各種管線，在科學、技術、疾病管理和護理方面彙集專家。以患者爲中心，由直接受到影響的人創立，Solid的使命是改善患有這些毀滅性疾病的患者的日常生活。更多信息，請訪問www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Solid Biosciences投資者聯繫方式：
Nicole Anderson
投資者關係和企業傳播董事Nicole Anderson
solid biosciences 公司。
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒體聯繫人：
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
Source: Solid Biosciences Inc.
來源：Solid Biosciences Inc.